Form 4: UTHR COO Benkowitz Exercises, Sells Shares

United Therapeutics Corp's President and COO, Michael Benkowitz, executed pre-planned stock option exercises and subsequent sales of common stock totaling 22,500 shares.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), engaged in transactions involving the exercise of stock options and the sale of common stock.
• These transactions were conducted on December 8, 2025, under a Rule 10b5-1 trading plan established on June 3, 2025.
• A total of 14,625 shares were acquired through option exercise at $117.76 per share and subsequently sold at $478.5778 per share. These shares were held in a trust where Benkowitz is a beneficiary and co-trustee with his spouse.
• An additional 7,875 shares were acquired through option exercise at $146.03 per share and subsequently sold at $478.5778 per share. These shares were held in a trust for family members, with Benkowitz having sole investment and voting power.
• Following these transactions, Benkowitz directly owns 2,648 shares of common stock.
• He also indirectly beneficially owns 155,625 stock options via Trust 2 and 14,065 stock options via Trust 3.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the insider executed a profitable transaction under a pre-planned arrangement, which is a routine event and not indicative of negative company performance. The sale reduces insider ownership but is offset by the pre-planned nature.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled personal financial event rather than a reaction to immediate company news.
• The sale price of $478.5778 per share is significantly higher than the exercise prices of $117.76 and $146.03, indicating a profitable transaction for the insider.

Negatives

• The President and COO reduced his beneficial ownership of common stock by selling 22,500 shares.

Future Outlook

NA

Industry Context

This filing details a routine insider transaction for an executive at a biotechnology company. Such transactions are common for executives managing their personal equity holdings and are typically not indicative of broader industry trends or competitive positioning.

Related Party Transactions

• The transactions involved trusts where the reporting person and/or his family members are beneficiaries, which are considered related party dealings in the context of beneficial ownership.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even if pre-planned, slightly reduces insider ownership, which some investors might view neutrally or with slight caution. However, the pre-planned nature mitigates concerns about opportunistic selling.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (exercise of options and sale of shares) by the President and COO. While it results in a reduction of direct common stock ownership, the execution under a Rule 10b5-1 plan suggests it's a personal financial management event rather than a signal about the company's immediate prospects. The significant profit realized by the insider from the option exercise is a positive for the individual but does not fundamentally alter the investment thesis for United Therapeutics. Therefore, the filing itself does not provide new information warranting a change in investment stance; a 'hold' recommendation is appropriate based solely on this disclosure.

Keywords

United Therapeutics, UTHR, Michael Benkowitz, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Executive Compensation, Biotechnology, Pharmaceuticals